1. Home
  2. |Insights
  3. |FERC/NERC Compliance Guidance Amid Potential Coronavirus Impacts

FERC/NERC Compliance Guidance Amid Potential Coronavirus Impacts

Client Alert | 1 min read | 03.19.20

The Federal Energy Regulatory Commission (FERC) and the North American Electric Reliability Corporation (NERC) jointly issued compliance guidance notifying NERC-registered entities that they will consider the impact of the coronavirus outbreak as an acceptable basis for noncompliance with certain NERC Reliability Standards and related activities, as follows: 

  • Noncompliance with obtaining and maintaining personnel certification under PER-003-2, for the period March 1, 2020 through December 31, 2020, except that registered entities must notify their Regional Entities and reliability coordinators when using system operator personnel that are not NERC-certified.
  • Noncompliance with Reliability Standard requirements involving periodic actions that would have to be taken between March 1, 2020 and July 31, 2020, except that registered entities must notify their Regional Entities of any periodic actions that will be missed during this period.
  • Regional Entities will postpone on-site audits, certifications, and other on-site activities through July 31, 2020.
  • Registered entities should communicate any coronavirus-related resource impacts associated with remote activities to their Regional Entities.

Please contact us if you have any questions regarding this guidance.

Contacts

Insights

Client Alert | 2 min read | 09.18.25

FDA Announces Intention to Initiate an Aggressive Enforcement Campaign Against Misleading Pharmaceutical Advertising

On September 9, 2025, the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (HHS) issued a news release announcing an “aggressive[]” “crackdown” on direct-to-consumer pharmaceutical advertising. This release came on the heels of a Presidential Memorandum President Trump issued the same day directing HHS to “ensure transparency and accuracy in direct-to-consumer prescription drug advertisements,” and the FDA to “take action to enforce legal requirements that advertisements for prescription drugs be truthful and not misleading.”...

View All Insights